Repligen Corporation (NASDAQ: RGEN) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Profitability

This table compares Repligen Corporation and TherapeuticsMD’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repligen Corporation 15.61% 9.90% 5.93%
TherapeuticsMD -485.71% -74.25% -66.61%

Institutional & Insider Ownership

96.5% of Repligen Corporation shares are owned by institutional investors. Comparatively, 71.6% of TherapeuticsMD shares are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by company insiders. Comparatively, 23.9% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Repligen Corporation and TherapeuticsMD’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Repligen Corporation $113.32 million 12.50 $29.54 million $0.51 74.35
TherapeuticsMD $18.26 million 56.98 -$88.99 million ($0.46) -11.09

Repligen Corporation has higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Repligen Corporation has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Repligen Corporation and TherapeuticsMD, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repligen Corporation 0 1 3 0 2.75
TherapeuticsMD 0 1 8 0 2.89

Repligen Corporation presently has a consensus target price of $46.00, suggesting a potential upside of 21.31%. TherapeuticsMD has a consensus target price of $14.88, suggesting a potential upside of 191.67%. Given TherapeuticsMD’s stronger consensus rating and higher possible upside, analysts plainly believe TherapeuticsMD is more favorable than Repligen Corporation.

Summary

Repligen Corporation beats TherapeuticsMD on 7 of the 13 factors compared between the two stocks.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.